Cargando…
Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
BACKGROUND: Limited information is available on the relevant prognostic variables after surgery for patients with pancreatic ductal adenocarcinoma (PDAC) subjected to neoadjuvant chemotherapy (NACT). NACT is known to induce a spectrum of histological changes in PDAC. Different grading regression sys...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072515/ https://www.ncbi.nlm.nih.gov/pubmed/35230580 http://dx.doi.org/10.1245/s10434-022-11413-7 |
_version_ | 1784701079122870272 |
---|---|
author | Redegalli, M. Schiavo Lena, M. Cangi, M. G. Smart, C. E. Mori, M. Fiorino, C. Arcidiacono, P. G. Balzano, G. Falconi, M. Reni, M. Doglioni, C. |
author_facet | Redegalli, M. Schiavo Lena, M. Cangi, M. G. Smart, C. E. Mori, M. Fiorino, C. Arcidiacono, P. G. Balzano, G. Falconi, M. Reni, M. Doglioni, C. |
author_sort | Redegalli, M. |
collection | PubMed |
description | BACKGROUND: Limited information is available on the relevant prognostic variables after surgery for patients with pancreatic ductal adenocarcinoma (PDAC) subjected to neoadjuvant chemotherapy (NACT). NACT is known to induce a spectrum of histological changes in PDAC. Different grading regression systems are currently available; unfortunately, they lack precision and accuracy. We aimed to identify a new quantitative prognostic index based on tumor morphology. PATIENTS AND METHODS: The study population was composed of 69 patients with resectable or borderline resectable PDAC treated with preoperative NACT (neoadjuvant group) and 36 patients submitted to upfront surgery (upfront-surgery group). A comprehensive histological assessment on hematoxylin and eosin (H&E) stained sections evaluated 20 morphological parameters. The association between patient survival and morphological variables was evaluated to generate a prognostic index. RESULTS: The distribution of morphological parameters evaluated was significantly different between upfront-surgery and neoadjuvant groups, demonstrating the effect of NACT on tumor morphology. On multivariate analysis for patients that received NACT, the predictors of shorter overall survival (OS) and disease-free survival (DFS) were perineural invasion and lymph node ratio. Conversely, high stroma to neoplasia ratio predicted longer OS and DFS. These variables were combined to generate a semiquantitative prognostic index based on both OS and DFS, which significantly distinguished patients with poor outcomes from those with a good outcome. Bootstrap analysis confirmed the reproducibility of the model. CONCLUSIONS: The pathologic prognostic index proposed is mostly quantitative in nature, easy to use, and may represent a reliable tumor regression grading system to predict patient outcomes after NACT followed by surgery for PDAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11413-7. |
format | Online Article Text |
id | pubmed-9072515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-90725152022-05-07 Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC) Redegalli, M. Schiavo Lena, M. Cangi, M. G. Smart, C. E. Mori, M. Fiorino, C. Arcidiacono, P. G. Balzano, G. Falconi, M. Reni, M. Doglioni, C. Ann Surg Oncol Pancreatic Tumors BACKGROUND: Limited information is available on the relevant prognostic variables after surgery for patients with pancreatic ductal adenocarcinoma (PDAC) subjected to neoadjuvant chemotherapy (NACT). NACT is known to induce a spectrum of histological changes in PDAC. Different grading regression systems are currently available; unfortunately, they lack precision and accuracy. We aimed to identify a new quantitative prognostic index based on tumor morphology. PATIENTS AND METHODS: The study population was composed of 69 patients with resectable or borderline resectable PDAC treated with preoperative NACT (neoadjuvant group) and 36 patients submitted to upfront surgery (upfront-surgery group). A comprehensive histological assessment on hematoxylin and eosin (H&E) stained sections evaluated 20 morphological parameters. The association between patient survival and morphological variables was evaluated to generate a prognostic index. RESULTS: The distribution of morphological parameters evaluated was significantly different between upfront-surgery and neoadjuvant groups, demonstrating the effect of NACT on tumor morphology. On multivariate analysis for patients that received NACT, the predictors of shorter overall survival (OS) and disease-free survival (DFS) were perineural invasion and lymph node ratio. Conversely, high stroma to neoplasia ratio predicted longer OS and DFS. These variables were combined to generate a semiquantitative prognostic index based on both OS and DFS, which significantly distinguished patients with poor outcomes from those with a good outcome. Bootstrap analysis confirmed the reproducibility of the model. CONCLUSIONS: The pathologic prognostic index proposed is mostly quantitative in nature, easy to use, and may represent a reliable tumor regression grading system to predict patient outcomes after NACT followed by surgery for PDAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11413-7. Springer International Publishing 2022-03-01 2022 /pmc/articles/PMC9072515/ /pubmed/35230580 http://dx.doi.org/10.1245/s10434-022-11413-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Pancreatic Tumors Redegalli, M. Schiavo Lena, M. Cangi, M. G. Smart, C. E. Mori, M. Fiorino, C. Arcidiacono, P. G. Balzano, G. Falconi, M. Reni, M. Doglioni, C. Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC) |
title | Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC) |
title_full | Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC) |
title_fullStr | Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC) |
title_full_unstemmed | Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC) |
title_short | Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC) |
title_sort | proposal for a new pathologic prognostic index after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma (pinc) |
topic | Pancreatic Tumors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072515/ https://www.ncbi.nlm.nih.gov/pubmed/35230580 http://dx.doi.org/10.1245/s10434-022-11413-7 |
work_keys_str_mv | AT redegallim proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc AT schiavolenam proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc AT cangimg proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc AT smartce proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc AT morim proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc AT fiorinoc proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc AT arcidiaconopg proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc AT balzanog proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc AT falconim proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc AT renim proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc AT doglionic proposalforanewpathologicprognosticindexafterneoadjuvantchemotherapyinpancreaticductaladenocarcinomapinc |